Last reviewed · How we verify

Adalimumab treatment arm

Medical University of Vienna · FDA-approved active Small molecule

Adalimumab treatment arm is a TNF-α inhibitor (monoclonal antibody) Small molecule drug developed by Medical University of Vienna. It is currently FDA-approved for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis. Also known as: Humira, Adalimumab.

Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.

At a glance

Generic nameAdalimumab treatment arm
Also known asHumira, Adalimumab
SponsorMedical University of Vienna
Drug classTNF-α inhibitor (monoclonal antibody)
TargetTNF-α (tumor necrosis factor-alpha)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in immune-mediated diseases. By preventing TNF-α from binding to its receptors on immune cells and other tissues, it suppresses the inflammatory cascade and reduces disease activity in autoimmune and inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adalimumab treatment arm

What is Adalimumab treatment arm?

Adalimumab treatment arm is a TNF-α inhibitor (monoclonal antibody) drug developed by Medical University of Vienna, indicated for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.

How does Adalimumab treatment arm work?

Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

What is Adalimumab treatment arm used for?

Adalimumab treatment arm is indicated for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis.

Who makes Adalimumab treatment arm?

Adalimumab treatment arm is developed and marketed by Medical University of Vienna (see full Medical University of Vienna pipeline at /company/medical-university-of-vienna).

Is Adalimumab treatment arm also known as anything else?

Adalimumab treatment arm is also known as Humira, Adalimumab.

What drug class is Adalimumab treatment arm in?

Adalimumab treatment arm belongs to the TNF-α inhibitor (monoclonal antibody) class. See all TNF-α inhibitor (monoclonal antibody) drugs at /class/tnf-inhibitor-monoclonal-antibody.

What development phase is Adalimumab treatment arm in?

Adalimumab treatment arm is FDA-approved (marketed).

What are the side effects of Adalimumab treatment arm?

Common side effects of Adalimumab treatment arm include Injection site reactions, Upper respiratory tract infections, Headache, Tuberculosis reactivation, Serious infections.

What does Adalimumab treatment arm target?

Adalimumab treatment arm targets TNF-α (tumor necrosis factor-alpha) and is a TNF-α inhibitor (monoclonal antibody).

Related